What top creators are saying about Celldex Therapeutics, Inc.(CLDX)

Biopharmaceutical company developing treatments for inflammatory diseases and cancer.

2 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.

Creator sentiment — last 30 days

Not enough scored insights about Celldex Therapeutics, Inc. in the last 30 days yet.

Top creators covering Celldex Therapeutics, Inc. (CLDX)

The 2 sources with the most insights about Celldex Therapeutics, Inc. on Kazuha.

Latest insights about Celldex Therapeutics, Inc. (CLDX)

AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.

Wednesday, September 23, 2026

Bullish
Target: $53

Its hives-drug data was described as strong, though speakers questioned the urgency and scale of the medical need; the stock rallied as much as 20–30% before fading.

Tuesday, September 22, 2026

Bullish

A speaker praised the company and its data, including a drug for hives, but the stock's 20–30% rally and subsequent fade highlighted volatility; no detailed trial or commercial analysis was provided.

Discussed alongside Celldex Therapeutics, Inc. (CLDX)

Other assets that creators frequently mention in the same content as Celldex Therapeutics, Inc..

Frequently asked

Which podcasters and creators cover Celldex Therapeutics, Inc. (CLDX) the most?

The most active sources covering Celldex Therapeutics, Inc. (CLDX) on Kazuha are @realmartinshkreli, @theshkrelipill. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.

How many insights about Celldex Therapeutics, Inc. (CLDX) are on Kazuha?

Kazuha has indexed 2 AI-extracted insights about Celldex Therapeutics, Inc. (CLDX) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.

What other assets do creators discuss alongside Celldex Therapeutics, Inc. (CLDX)?

Creators covering Celldex Therapeutics, Inc. (CLDX) most frequently also discuss DOGE, IOVA, LRCX, INTC, AMD. See the "Discussed alongside" section above for full asset pages.